日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis

GLP-1受体激动剂与DPP-4抑制剂和基础胰岛素治疗2型糖尿病的心血管和肾脏结局：系统评价和荟萃分析

期刊:
影响因子:
doi:10.1177/14791641231221740
Evans, Marc; Kuodi, Paul; Akunna, Chisom Joyqueenet; McCreedy, Nicole; Donsmark, Morten; Ren, Hongye; Nnaji, Chukwudi A
GLP-1
信号转导
代谢
糖尿病
免疫/内分泌
发表日期：2023
文献求助 收藏

Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation

不同给药条件对口服索马鲁肽（一种人胰高血糖素样肽-1类似物）片剂药代动力学的影响

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-021-01078-y
Bækdal, Tine A; Breitschaft, Astrid; Donsmark, Morten; Maarbjerg, Stine J; Søndergaard, Flemming L; Borregaard, Jeanett
Human
发表日期：2021
文献求助 收藏

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

将监管指南纳入糖尿病临床试验并加以解读：以PIONEER 1随机临床试验为例

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.13804
Aroda, Vanita R; Saugstrup, Trine; Buse, John B; Donsmark, Morten; Zacho, Jeppe; Davies, Melanie J
糖尿病
代谢
发表日期：2019
文献求助 收藏

Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme

根据基线体重指数评估糖化血红蛋白的改善情况：利拉鲁肽 III 期临床试验项目的荟萃分析

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.12617
Montanya, E; Fonseca, V; Colagiuri, S; Blonde, L; Donsmark, M; Nauck, M A
发表日期：2016
文献求助 收藏

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials

利拉鲁肽降低 2 型糖尿病患者收缩压：来自六项随机临床试验的患者水平汇总分析的见解

期刊:Journal of Diabetes and Its Complications
影响因子:3.1
doi:10.1016/j.jdiacomp.2014.01.009
Fonseca, Vivian A; Devries, J Hans; Henry, Robert R; Donsmark, Morten; Thomsen, Henrik F; Plutzky, Jorge
糖尿病
代谢
发表日期：2014
文献求助 收藏